08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On March 16, 2020, in response to the COVID-19 (coronavirus) global pandemic, seven counties – Alam...
Read More >
Next month, Connecticut legislators from across the political spectrum are set to formally introduce...
Read More >
A California federal judge today granted the U.S. Women’s National Team an early victory in their p...
Read More >
In the belatedly-published Environmental Council of Sacramento, et al. v. County of Sacramento (Cord...
Read More >
While some have been enjoying the return of baseball, albeit without fans in the stands, the Oakland...
Read More >
The holiday season is nearly upon us, and the shopping frenzy is about to commence. This annual phen...
Read More >